Poongjeon Pharmacy rights offering: 1,200,000 new shares, ₩3.0bn
Poongjeon Pharmacy filed a rights offering for 1,200,000 new shares, equal to 12.5% of existing shares by our calculation, with an issue amount of ₩3.0bn. The allocation method is third-party allotment and the main purpose of the funds is operating funds. The issue amount equals 12.6% of FY2025 revenue by our calculation.
Key facts
| New shares | 1,200,000 shares |
|---|---|
| New shares as % of existing shares (calculated) | 12.5% |
| Issue amount | ₩3.0bn |
| Main purpose of funds | Operating funds |
| Allocation method | Third-party allotment |
Comparison
| Amount as % of FY2025 revenue (calculated) | 12.6% |
|---|---|
| Revenue 2025 | ₩23.8bn |
| Revenue 2024 | ₩825m |
| Revenue 2023 | ₩696m |
Context
In the 12 months before this filing, the company issued ₩2.0bn in CB/BW/EB across 1 issue and 796,812 shares in rights offerings.
Key metrics
Potential dilution
| CB/BW/EB issued, last 12 months | ₩2.0bn |
|---|---|
| Rights offering new shares, last 12 months | 1,996,812 shares |
| Potential new shares, last 12 months | 4,463,078 shares (1 upward conversion price adjustment not netted) |
| Potential new shares, % of shares | 46.3% (1 upward conversion price adjustment not netted) |
| Conversion price adjustments, last 12 months | 4 |
Source: DART (Financial Supervisory Service) · Original filing on DART ↗